Journal of Viral Hepatitis · 2021 · 27 citations · 9 references
Public HealthBiostatisticsInfectious Disease ControlEpidemiologic MethodsEpidemiologyHealth Services ResearchCausal Effect EstimationChronic Hepatitis ManagementDisease ControlTreatment EffectivenessViral Hepatitis TreatmentBayesian Binomial RegressionBayesian Inference For Poisson ProcessesBinomial RegressionChronic Viral HepatitisHepatitis C InfectionIntegrated Delivery NetworksOdds Ratio InterpretationOdds Ratio Modeling
Many people with chronic hepatitis C infection don't engage in treatment. To eliminate hepatitis C and avoid health inequalities therapy must be provided to everyone. In other diseases peers with lived experience of the condition have improved care but, for hepatitis C, studies have not shown unequivocal benefit. We completed a retrospective analysis of the English National Health Service treatment registry comparing treatment networks with and without peers using Bayesian Poisson (for count outcomes) or Bayesian Binomial (for proportion outcomes) mixed effects models with time fixed effects. For each outcome, we estimated relative ratio (RR-Poisson model) or odds ratio (Odds Ratio (OR)-Binomial model) between peer and non-peer networks. We analysed 30,729 patients within 20 operational delivery networks. In networks with peers there was an increase in the number of people initiating therapy (RR 1.12 95%, credible interval 1.02-1.21) and an increase in the proportion completing therapy (OR 2.45 95%, credible interval 1.49-3.84). However, we saw no change in proportions of people using drugs who initiated therapy nor any significant change in virological response (OR 1.14 95% credible interval 0.979-1.36). We repeated the analysis looking at the impact of peers two months after they had been introduced, when they had established networks of contacts, and saw an increase in the proportion of people treated in addiction services. In treating patients with chronic hepatitis C infection the inclusion of peer supporters may increase the number of people who initiate and complete antiviral therapy.
9
Jessica F. Magidson, John A. Joska, Kristen S. Regenauer et al. · International Journal of Drug Policy · 2019 · 79 citations · Full text
Sahar Bajis, Jason Grebely, Behzad Hajarizadeh et al. · Journal of Viral Hepatitis · 2019 · 54 citations · Full text
Kathleen Ward, Oluwaseun Falade‐Nwulia, Juhi Moon et al. · Open Forum Infectious Diseases · 2019 · 47 citations · Full text
Ivdity Chikovani, Danielle C. Ompad, Maia Uchaneishvili et al. · PLoS ONE · 2019 · 47 citations · Full text